Compare VIVK & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIVK | NXL |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 18.6M |
| IPO Year | N/A | 2022 |
| Metric | VIVK | NXL |
|---|---|---|
| Price | $0.06 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 25.6M | 113.8K |
| Earning Date | 11-19-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,113,426.00 | $156,931.00 |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | N/A | $185.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 101.82 | N/A |
| 52 Week Low | $0.06 | $0.70 |
| 52 Week High | $1.49 | $4.19 |
| Indicator | VIVK | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 27.38 | 31.12 |
| Support Level | $0.06 | $0.93 |
| Resistance Level | $0.09 | $1.01 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 10.37 | 2.99 |
Vivakor Inc is a socially responsible operator, acquirer and developer of technologies and assets in the oil and gas industry, as well as related environmental solutions. It is focused on operating crude oil gathering, storage and transportation facilities, as well as contaminated soil remediation services. Company have two operating business segments: Transportation logistics services; Terminaling and storage facility product and services related to oil and gas production. Majority of revenue is from Terminaling and storage segment.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.